Literature DB >> 33733654

Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population.

Ana M Cebrián-Cuenca1, Manel Mata-Cases2,3,4, Josep Franch-Nadal3,4,5, Dídac Mauricio3,4,6, Domingo Orozco-Beltrán7, Luciano Consuegra-Sánchez8.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 33733654     DOI: 10.1093/eurjpc/zwaa073

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


× No keyword cloud information.
  5 in total

1.  Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.

Authors:  Augusto Lavalle-Cobo; Walter Masson; Martín Lobo; Gerardo Masson; Graciela Molinero
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-10-27

Review 2.  Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease.

Authors:  Xiao-Ying Li; Li Li; Sang-Hoon Na; Francesca Santilli; Zhongwei Shi; Michael Blaha
Journal:  Am J Prev Cardiol       Date:  2022-06-06

3.  Sex Differences in Cardiovascular Prevention in Type 2: Diabetes in a Real-World Practice Database.

Authors:  Anna Ramírez-Morros; Josep Franch-Nadal; Jordi Real; Mònica Gratacòs; Didac Mauricio
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

4.  Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.

Authors:  Mario Luca Morieri; Olga Lamacchia; Enzo Manzato; Andrea Giaccari; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2022-04-26       Impact factor: 8.949

5.  Cardiovascular risk in newly diagnosed type 2 diabetes patients in India.

Authors:  A G Unnikrishnan; R K Sahay; Uday Phadke; S K Sharma; Parag Shah; Rishi Shukla; Vijay Viswanathan; S K Wangnoo; Santosh Singhal; Mathew John; Ajay Kumar; Mala Dharmalingam; Subodh Jain; Shehla Shaikh; Willem J Verberk
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.